Our results indicate that effects beyond the renewal of adaptive immune cells, namely beyond CD4+ and CD8+ T cells and B cells, may contribute to the excellent treatment effects of aHSCT in MS. The gene discussed is CD8A; the disease is myeloid sarcoma.